Early deep response to cilta-cel as 2nd CAR T-Cell therapy after CELMoD-based bridging for advanced multiple myeloma.
Henrik Niklas, Anna Bold, Simon Völkl et al.
✦ AI-curated · Sources linked
Case in brief
A 58-year-old male with high-risk IgA kappa multiple myeloma, previously treated with multiple therapies, received idecabtagene vicleucel as sixth-line treatment, achieving a deep response for about one year. Upon progression, he underwent bridging therapy with mezigdomide, carfilzomib, and dexamethasone, followed by a second BCMA-directed CAR T-cell therapy with ciltacabtagene autoleucel, resulting in a rapid and profound response.
Diagnostic / clinical pearl
This case highlights the potential for effective retreatment with BCMA-directed CAR T-cell therapy in heavily pretreated multiple myeloma patients, especially after a prior durable response.
Why it matters
The findings suggest that bridging therapy and alternative CAR T-cell constructs may enhance outcomes, warranting further investigation into optimal treatment strategies for relapsed/refractory multiple myeloma.